CrystalGenomics joins hands with AstraZeneca

Published: 2010-01-14 06:57:00

Updated: 2010-01-14 06:57:00

CrystalGenomics Inc., a local biopharmaceutical company, services, said on January 12 that it has signed a contract with AstraZeneca Plc to jointly develop a new antibiotic to treat superbacteria.

Financial terms of the contract were not disclosed. Under the contract, London-based AstraZeneca ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK